We are live on ! Find out more
SGNT

SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT

Delisted

SGNT was delisted on the 29th of August, 2016.

99 hedge funds and large institutions have $560M invested in SAGENT PHARMACEUTICALS INC COM STK (DE) in 2013 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 36 increasing their positions, 33 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

28% more capital invested

Capital invested by funds: $436M → $560M (+$124M)

9% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 33

4% less funds holding

Funds holding: 10399 (-4)

15% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 26

Holders
99
Holders Change
-4
Holders Change %
-3.88%
% of All Funds
2.87%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.06%
New
22
Increased
36
Reduced
33
Closed
26
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Franklin Resources
1
Franklin Resources
California
$115M +$12.9M +569,681 +14%
Morgan Stanley
2
Morgan Stanley
New York
$95.8M -$2.12M -94,044 -2%
Vanguard Group
3
Vanguard Group
Pennsylvania
$29.7M +$2.28M +100,947 +9%
CS
4
Credit Suisse
Switzerland
$26.8M -$13.8M -613,296 -37%
BFA
5
BlackRock Fund Advisors
California
$21M +$7.79M +345,054 +71%
JP Morgan Chase
6
JP Morgan Chase
New York
$17.7M -$7.2M -318,621 -31%
SAM
7
Sectoral Asset Management
Quebec, Canada
$17.5M +$2.83M +125,404 +22%
PCM
8
Penn Capital Management
Pennsylvania
$17.4M +$11.5M +508,086 +289%
NIMC
9
NWQ Investment Management Company
California
$17.2M +$15.3M +675,935 New
Goldman Sachs
10
Goldman Sachs
New York
$14.1M +$561K +24,864 +5%
Jennison Associates
11
Jennison Associates
New York
$13.1M -$504K -22,299 -4%
Loomis, Sayles & Company
12
Loomis, Sayles & Company
Massachusetts
$12.9M +$11.5M +507,928 New
Millennium Management
13
Millennium Management
New York
$8.89M -$3.29M -145,481 -29%
BC
14
Broadfin Capital
New York
$8.16M +$5.72M +253,088 +371%
TCM
15
Tekla Capital Management
Massachusetts
$8.1M +$1.11M +49,200 +18%
State Street
16
State Street
Massachusetts
$7.43M +$1.09M +48,291 +20%
Mackenzie Financial
17
Mackenzie Financial
Ontario, Canada
$7.11M +$6.33M +280,300 New
Northern Trust
18
Northern Trust
Illinois
$7M +$776K +34,354 +14%
Fidelity Investments
19
Fidelity Investments
Massachusetts
$6.65M +$5.92M +262,000 New
Charles Schwab
20
Charles Schwab
California
$6.47M +$321K +14,226 +6%
BIT
21
BlackRock Institutional Trust
California
$6.06M -$377K -16,700 -7%
BIM
22
Bogle Investment Management
Massachusetts
$4.27M
Federated Hermes
23
Federated Hermes
Pennsylvania
$4.15M -$3.76M -166,700 -50%
CM
24
Castleark Management
Illinois
$4.06M +$3.62M +160,100 New
Zurich Cantonal Bank
25
Zurich Cantonal Bank
Switzerland
$3.81M +$3.39M +150,000 New

SGNT Hedge Fund Activity: Q4 2013 in Review

99 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) for Q4 2013, worth a combined $560M — up 28% from $436M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of SGNT and 22 opened new positions — a net loss of 4 holders — while 33 trimmed existing stakes and 36 added.

The largest buyer was NWQ Investment Management Company, opening a new position worth an estimated $15.3M. The largest seller was Deerfield Management, exiting entirely with an estimated $20.7M sold.

  • 99 institutional investors held SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) as of Q4 2013, down from 103 in Q3 2013.
  • Funds reported $560M of SAGENT PHARMACEUTICALS INC COM STK (DE) stock for Q4 2013, up 28% quarter-over-quarter.
  • 22 funds opened new SAGENT PHARMACEUTICALS INC COM STK (DE) positions in Q4 2013 and 26 closed out, a net change of -4 holders.
  • The largest SAGENT PHARMACEUTICALS INC COM STK (DE) buyer in Q4 2013 was NWQ Investment Management Company, an estimated $15.3M added.
  • The largest SAGENT PHARMACEUTICALS INC COM STK (DE) seller in Q4 2013 was Deerfield Management, an estimated $20.7M sold.

Based on aggregated 13F filings for Q4 2013.